Found 3427 clinical trials
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
The primary objective of the study is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine is given concomitantly with routine pediatric …
- 0 views
- 19 Feb, 2024
- 29 locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
The primary objective of the study is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine is given concomitantly with routine pediatric …
- 0 views
- 19 Feb, 2024
- 29 locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4) To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of …
- 0 views
- 19 Feb, 2024
- 32 locations
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
- 0 views
- 19 Feb, 2024
- 1 location
Combining Biomarkers (AFP AFP-L3 and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in …
- 0 views
- 19 Feb, 2024
- 15 locations
Hepatitis C Virus (HVC) Positive Heart Grafts in HCV Negative Recipients
To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor grafts in HCV negative heart recipients who are currently listed.
- 0 views
- 19 Feb, 2024
- 1 location
HCV Reinfection After DAA Therapy in PWID in Belgium
The primary aim of this study is to calculate the incidence of HCV reinfection after successful DAA treatment among people who have recently injected drugs. The secondary aim is to identify factors associated with reinfection in this population. Individuals with active injecting drug abuse with a chronic HCV infection who …
- 0 views
- 19 Feb, 2024
- 10 locations
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and excess fat in the liver. Surgical excision of these liver lesions is the reference treatment but it cannot always be realised.
- 0 views
- 19 Feb, 2024
- 1 location
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).
- 0 views
- 19 Feb, 2024
- 1 location
Longitudinal Immune-phenotyping of HCC Following MK-3475
The study comprises a main study of pembro-treated HCC patients and a sub-study of untreated HCC patients. In the main study, patients will be treated with pembrolizumab as neoadjuvant treatment approximately 4 weeks prior scheduled surgery. Adjuvant treatment with pembrolizumab with commence at approximately 4 weeks post-surgery for up to …
- 0 views
- 19 Feb, 2024
- 1 location